Nasus Pharma Ltd (NSRX): R&D Expense
Figures out of scale. In this company's filings, reported revenue for the year ended 2025-12-31 is more than 100 times total assets. That usually means a value was tagged in the wrong unit. Figures are shown as filed; growth rates are not computed, and the company is left out of screens and comparisons.
$2.24M
Year ended 2025-12-31. As filed; likely tagged in the wrong unit
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.24M | n/a | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $335.0K | n/a | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $567.0K | n/a | 2026-03-25, From 2023-01-01 |